Immunome (NASDAQ:IMNM) Now Covered by Stephens

Stephens initiated coverage on shares of Immunome (NASDAQ:IMNM) in a research note released on Friday, Marketbeat Ratings reports. The firm issued an overweight rating and a $30.00 price objective on the stock.

IMNM has been the topic of a number of other reports. Piper Sandler cut their target price on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Friday, October 25th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $29.17.

Immunome Stock Up 3.5 %

NASDAQ IMNM traded up $0.44 on Friday, hitting $12.98. 547,758 shares of the company were exchanged, compared to its average volume of 526,121. Immunome has a 1-year low of $6.93 and a 1-year high of $30.96. The firm has a 50 day moving average of $13.39 and a two-hundred day moving average of $13.88.

Immunome (NASDAQ:IMNM) last released its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. On average, research analysts expect that Immunome will post -1.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Max Rosett sold 14,380 shares of the stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at approximately $760,090.76. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Max Rosett sold 14,380 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the transaction, the chief financial officer now directly owns 47,476 shares of the company’s stock, valued at $760,090.76. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the purchase, the director now directly owns 16,615 shares in the company, valued at approximately $231,613.10. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 8.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Immunome

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its position in Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after buying an additional 1,194,451 shares during the period. Marshall Wace LLP lifted its stake in shares of Immunome by 228.5% in the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after acquiring an additional 1,191,774 shares during the period. Redmile Group LLC lifted its stake in Immunome by 26.0% in the first quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after buying an additional 1,010,139 shares during the period. Farallon Capital Management LLC acquired a new position in Immunome in the first quarter valued at approximately $14,660,000. Finally, Lord Abbett & CO. LLC acquired a new position in Immunome in the first quarter valued at approximately $10,994,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.